Stock analysts at Roth Capital initiated coverage on shares of Galectin Therapeutics Inc. (NASDAQ:GALT) in a note issued to investors on Thursday. The brokerage set a “buy” rating and a $8.00 price target on the stock. Roth Capital’s price target indicates a potential upside of 218.73% from the company’s previous close.

Several other research firms also recently commented on GALT. ValuEngine downgraded shares of Galectin Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Seaport Global Securities restated a “buy” rating and issued a $5.00 price target on shares of Galectin Therapeutics in a research note on Friday, October 6th. Finally, Zacks Investment Research downgraded shares of Galectin Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 18th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $4.63.

Galectin Therapeutics (NASDAQ:GALT) traded up 3.1912% during trading on Thursday, hitting $2.5901. 109,587 shares of the stock were exchanged. Galectin Therapeutics has a 52 week low of $0.49 and a 52 week high of $3.68. The firm has a 50-day moving average of $2.09 and a 200-day moving average of $2.34. The stock’s market capitalization is $90.79 million.

Galectin Therapeutics (NASDAQ:GALT) last released its quarterly earnings results on Monday, August 14th. The company reported ($0.14) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.01. During the same quarter last year, the company earned ($0.20) earnings per share. Equities research analysts anticipate that Galectin Therapeutics will post ($0.49) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Galectin Therapeutics Inc. (GALT) Now Covered by Roth Capital” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/10/19/galectin-therapeutics-inc-galt-now-covered-by-roth-capital.html.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Northern Trust Corp lifted its position in Galectin Therapeutics by 4.4% during the second quarter. Northern Trust Corp now owns 75,097 shares of the company’s stock worth $185,000 after purchasing an additional 3,176 shares during the period. KCG Holdings Inc. lifted its position in Galectin Therapeutics by 1.9% during the first quarter. KCG Holdings Inc. now owns 86,195 shares of the company’s stock worth $198,000 after purchasing an additional 1,592 shares during the period. Virtu KCG Holdings LLC lifted its position in Galectin Therapeutics by 24.4% during the second quarter. Virtu KCG Holdings LLC now owns 107,203 shares of the company’s stock worth $264,000 after purchasing an additional 21,008 shares during the period. Advisor Group Inc. lifted its position in Galectin Therapeutics by 10.4% during the second quarter. Advisor Group Inc. now owns 484,000 shares of the company’s stock worth $1,191,000 after purchasing an additional 45,700 shares during the period. Finally, Vanguard Group Inc. lifted its position in Galectin Therapeutics by 18.2% during the second quarter. Vanguard Group Inc. now owns 871,510 shares of the company’s stock worth $2,144,000 after purchasing an additional 134,165 shares during the period. 11.18% of the stock is owned by institutional investors and hedge funds.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.

Receive News & Stock Ratings for Galectin Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. and related stocks with our FREE daily email newsletter.